Millipore Sigma Vibrant Logo

532606 5-Lipoxygenase Inhibitor, MK591 - CAS 147030-01-1 - Calbiochem

532606
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₃₄H₃₄ClN₂NaO₃S 147030-01-1

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
5.32606.0001
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 5 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA cell permeable, bioavailable, 2-indolealkanoic acid derived compound that acts as a highly potent and selective inhibitor of leukotriene biosynthesis (IC50 = 3.1 nM in intact human polymorphonuclear leukocytes). Shown to inhibit 5-lipoxygenase (5-LOX) activity in LNCaP prostate cancer cells by high-affinity binding to 5-lipoxygenase activating protein (FLAP; IC50 = 1.6 nM in a FLAP binding assay). Induces apoptosis in LNCaP cells without blocking PI 3 kinase-Akt or ERK activities. Also shown to induce rapid phosphorylation of c-Jun N-terminal Kinase (JNK) and indirectly block PKCε activity. Suppresses the deposition of Ab1-40 and Ab1-42 peptides in Tg2576 mice (~40 mg/kg/day in diet) with concomitant reduction in the levels of presenilin 1, nicastrin, APH-1 and Pen-2, but without affecting notch signaling. Exhibits desirable pharmacokinetic properties with tmax of 3.3 h and t1/2 = ~12 h.

      Please note that the molecular weight for this compound is batch-specific due to variable water content.
      Catalogue Number532606
      Brand Family Calbiochem®
      SynonymsFLAP Inhibitor, MK591, sodium 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropanoate, L-686,708, MK-0591
      References
      ReferencesChu, J., et al. 2012. J. Neuroinflamm. 9, 127.
      Sarveswaran, S., et al. 2011. Bioch. Biophy. Acta. 1813, 2108.
      Sarveswaran, S., et al. 2010. Cancer Lett. 291, 167.
      Uematsu, T., et al. 1995. Br. J. Clin. Pharm. 40, 59.
      Product Information
      CAS number147030-01-1
      FormWhite solid
      Hill FormulaC₃₄H₃₄ClN₂NaO₃S
      Chemical formulaC₃₄H₃₄ClN₂NaO₃S
      ReversibleY
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetFLAP
      Primary Target IC<sub>50</sub>3.1 nM
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      5-Lipoxygenase Inhibitor, MK591 - CAS 147030-01-1 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      References

      Reference overview
      Chu, J., et al. 2012. J. Neuroinflamm. 9, 127.
      Sarveswaran, S., et al. 2011. Bioch. Biophy. Acta. 1813, 2108.
      Sarveswaran, S., et al. 2010. Cancer Lett. 291, 167.
      Uematsu, T., et al. 1995. Br. J. Clin. Pharm. 40, 59.

      Brochure

      Title
      NPI Flyer- Epigenetics and Nuclear Function Feature (EMD)
      New Products - Antibodies, Small Molecule, Inhibitors

      Technical Info

      Title
      White Paper: Further considerations of antibody validation and usage. (EMD)
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision19-December-2014 JSW
      SynonymsFLAP Inhibitor, MK591, sodium 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropanoate, L-686,708, MK-0591
      DescriptionA cell permeable, bioavailable, 2-indolealkanoic acid derived compound that acts as a highly potent and selective inhibitor of leukotriene biosynthesis (IC50 = 3.1 nM in intact human polymorphonuclear leukocytes). Shown to inhibit 5-lipoxygenase (5-LOX) activity in LNCaP prostate cancer cells by high-affinity binding to 5-lipoxygenase activating protein (FLAP; IC50 = 1.6 nM in a FLAP binding assay). Induces apoptosis in LNCaP cells without blocking PI 3 kinase-Akt or ERK activities. Also shown to induce rapid phosphorylation of c-Jun N-terminal Kinase (JNK) and indirectly block PKCε activity. Suppresses the deposition of Ab1-40 and Ab1-42 peptides in Tg2576 mice (~40 mg/kg/day in diet) with concomitant reduction in the levels of presenilin 1, nicastrin, APH-1 and Pen-2, but without affecting notch signaling. Exhibits desirable pharmacokinetic properties with tmax of 3.3 h and t1/2 = ~12 h.
      FormWhite solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number147030-01-1
      Chemical formulaC₃₄H₃₄ClN₂NaO₃S
      Purity≥98% by HPLC
      SolubilityDMSO (10 mg/ml)
      Storage -20°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesChu, J., et al. 2012. J. Neuroinflamm. 9, 127.
      Sarveswaran, S., et al. 2011. Bioch. Biophy. Acta. 1813, 2108.
      Sarveswaran, S., et al. 2010. Cancer Lett. 291, 167.
      Uematsu, T., et al. 1995. Br. J. Clin. Pharm. 40, 59.